Key Takeaways
- Of the 460 big funds that have filed 13Fs for the quarter ended Sept. 30, 26 bought Danaher and 14 sold it, including Stanley Druckenmiller’s Duquesne Family Office and Dan Loeb’s Third Point.
- The buyers put in far more money. Dodge & Cox led them with about $2.18 billion of added shares.
- Lone Pine and Maverick Capital also opened positions in Thermo Fisher, while Duquesne sold out of both stocks.
- Danaher’s earnings are growing again and the stock trades below its average multiple, so the buyers have the better case.
Stanley Druckenmiller and Dan Loeb both sold out of Danaher (DHR) last quarter. Dodge & Cox did the opposite and added about $2.18 billion of shares.
All three moves show up in 13Fs for the quarter ended Sept. 30. Of the 460 big funds that have filed for the quarter (funds readers know, plus any with $1 billion or more of US stocks in its 13F, with quant and index funds left out), 26 bought Danaher, either as a new position or by adding 20% or more to their shares. Fourteen sold out or cut 20% or more, and 65 held it at the quarter’s end.
The sellers had less riding on it
Druckenmiller’s Duquesne sold all 50,300 of its shares, about $10 million at Sept. 30 prices. That stake was only 0.2% of its 13F stocks at the end of June. Loeb’s Third Point sold all 540,000 of its shares, about $103 million, which was 2.2% of its 13F stocks in June.
Generation Investment Management made the biggest sale in dollars. It cut its stake 25%, to 5.09 million shares from 6.76 million, which is about $369 million. Even after the cut, Danaher was still its second-largest holding on Sept. 30, at 12.0% of the $9.4 billion of US stocks in its 13F. Dorsey Asset Management’s exit means more, because it sold all 626,211 of its shares in a position that had been 7.6% of its 13F stocks in June.
TIKR tracks 24 analysts on Danaher. How many say “Buy”?
See the full breakdown of Buy, Hold, and Sell ratings on Danaher, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See Danaher’s Analyst Ratings
The buyers brought far more money
Dodge & Cox manages $467 billion. It took its stake to 10.08 million shares from 257,039. That’s about $2.18 billion of stock but only 1.2% of its 13F stocks, and still no seller moved anything close to that amount. Lone Pine Capital, a $22 billion hedge fund, opened a 4.94 million-share position worth about $1.10 billion. That made Danaher its second-largest holding, at 7.1% of its 13F stocks. Lee Ainslie’s Maverick Capital opened one too: 2.21 million shares, about $490 million, or 3.9% of its 13F stocks.
Some well-known names also bought. Andreas Halvorsen’s Viking Global opened a position worth about $231 million. Chase Coleman’s Tiger Global nearly tripled its stake to 1.27 million shares, and Dan Sundheim’s D1 Capital added 32% to reach 3.02 million shares.
Lone Pine and Maverick also opened new positions in Thermo Fisher Scientific (TMO), worth $673 million and $201 million. Duquesne sold all 19,200 of its Thermo Fisher shares as well. A 13F only shows what a fund held on June 30 and Sept. 30, so we can’t tell when in the quarter anyone traded or why. Still, these three funds made the same move on both of the biggest lab-tools makers. Thermo Fisher trades at about 26x forward earnings, and analysts’ average target is 10% above its last close, compared with 14% for Danaher.
The buyers have the numbers
On Oct. 21, Danaher beat its third-quarter estimates, with trends improving across its end markets. Sales rose 8.5% to $6.55 billion, and adjusted EPS rose 11.5% to $2.11, according to its third-quarter release. Core revenue grew 3.0%, or 5.5% without respiratory testing. Danaher also raised its 2026 adjusted EPS guidance to $8.57-$8.62 from $8.45-$8.60, and analysts’ $8.59 consensus falls inside that range.
After three years stuck between $7.48 and $7.80 a share, analysts expect normalized EPS to reach $10.29 by 2028:

Investors aren’t paying a premium for that growth. Danaher trades at 25x forward earnings, below its five-year average of 27x and well under its 35x peak in August 2024:

The multiple was as low as 19x in May, though, so the market has already priced in some of the recovery.
The 24 analysts who cover Danaher have an average target of $259.90, 14% above the last close and up from $254.20 a year ago:

Measured against the 2028 estimate of $10.29, that target works out to about 25x, close to today’s multiple. So Danaher doesn’t need a higher multiple to get there. It only needs the estimates to hold.
I’d side with the buyers
The main risk is growth outside respiratory testing. Danaher’s guidance calls for 4% to 5% core growth without respiratory in the fourth quarter, slower than the 5.5% it just reported. Dorsey’s full exit is the strongest sign that a serious holder had seen enough. Still, earnings are growing again, guidance went up, and the stock trades below its usual multiple. On those numbers, the buyers look right to me.
The fourth-quarter report, expected in late January, is the next test. Core growth of 4% to 5% without respiratory and 2026 adjusted EPS of at least $8.57 would keep the buyers’ case on track. The next 13Fs, for the quarter ending Dec. 31, are due in mid-February and will show whether Lone Pine and Dodge & Cox kept adding.
So what is Danaher stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what Danaher could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!